USANA Health Sciences, Inc. (NYSE:USNA) Director Myron W. Wentz sold 17,107 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $65.42, for a total transaction of $1,119,139.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.54%. The company had revenue of $261.77 million during the quarter, compared to the consensus estimate of $259.52 million. During the same quarter in the previous year, the firm earned $2.40 earnings per share. The firm’s quarterly revenue was up 3.0% on a year-over-year basis.

USANA Health Sciences announced that its Board of Directors has authorized a stock repurchase program on Tuesday, July 25th that authorizes the company to buyback $64.60 million in shares. This buyback authorization authorizes the company to buy up to 46% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

WARNING: “USANA Health Sciences, Inc. (USNA) Director Myron W. Wentz Sells 17,107 Shares” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/usana-health-sciences-inc-usna-director-myron-w-wentz-sells-17107-shares.html.

A number of equities research analysts recently commented on the stock. BidaskClub raised shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Pivotal Research cut their price target on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, July 26th.

Large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its position in shares of USANA Health Sciences by 13.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock worth $135,000 after buying an additional 245 shares during the last quarter. Victory Capital Management Inc. lifted its position in shares of USANA Health Sciences by 124.7% during the 1st quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock worth $122,000 after buying an additional 1,175 shares during the last quarter. Creative Planning lifted its position in shares of USANA Health Sciences by 528.0% during the 2nd quarter. Creative Planning now owns 2,512 shares of the company’s stock worth $161,000 after buying an additional 2,112 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $162,000. Finally, Eqis Capital Management Inc. purchased a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $210,000. Institutional investors and hedge funds own 44.62% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.